Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJpel Priv Eqty Regulatory News (JPEL)

Share Price Information for Jpel Priv Eqty (JPEL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.89
Bid: 0.86
Ask: 0.92
Change: 0.00 (0.00%)
Spread: 0.06 (6.977%)
Open: 0.89
High: 0.89
Low: 0.89
Prev. Close: 0.89
JPEL Live PriceLast checked at -
JPEL Private Equity is an Investment Trust

To effect an orderly realisation of the investments and other assets comprised in the portfolio of the company and will seek to realise such investments and assets in order to maximise returns to US equity shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Statement re: Valuation Reporting Frequency

12 Feb 2010 09:31

RNS Number : 0700H
J.P. Morgan Private Equity Ltd
12 February 2010
 



J.P. Morgan Private Equity Increases Frequency of Private Equity Valuation Reporting

 * * *

GUERNSEY, 12 FEBRUARY 2010

J.P. Morgan Private Equity Limited ("JPEL" or the "Company"), the London Stock Exchange listed private equity secondary fund, is pleased to announce that the Company will be increasing the frequency of the reporting and valuation of its private equity portfolio.

Since the Company's IPO at June 2005, JPEL has updated the values of its private equity portfolio on a quarterly basis. Beginning with the month that ended 31 January 2010, the Company began valuing its private equity portfolio on a monthly basis.

Since inception, JPEL has always placed emphasis on investor communications and reporting. Increasing the frequency of valuations for the private equity portfolio is a logical and welcomed continuation of this effort. The Manager believes that reporting private equity valuations twelve times per year will enable the Manager to efficiently communicate its activity in the secondary market as well as the overall performance of the portfolio.

JPEL's primary strategy is to acquire secondary market portfolios of direct fund investments, significantly invested partnership interests and partially drawn commitments, in order to accelerate NAV development. JPEL employs an opportunistic, deep value private equity investment strategy and focuses on value-oriented investments with potential for early return of capital. From inception through 31 December 2009, JPEL's NAV per US$ Equity Share has grown 25.5% versus declines of 6.4% and 47.5% in the S&P 500 and LPX indices, respectively.

Please refer to page 2 of this press release for additional information on JPEL's Valuation and Reporting Policy.

* * *

About J.P. Morgan Private Equity Limited

J.P. Morgan Private Equity Limited is a Guernsey registered and incorporated, London Stock Exchange-listed, closed-ended investment company (LSE: JPEL, JPEZ, JPZZ) designed primarily to invest in the global private equity market. The investment objective of the Company is to achieve both short and long-term capital appreciation by investing in a well diversified portfolio of private equity fund interests and by capitalising on the inefficiencies of the secondary private equity market. The Company's capital structure consists of three classes of shares: Equity Shares and two classes of Zero Dividend Preference Shares due 2013 and 2015, respectively. JPEL issued warrants free of subscription cost to shareholders on record as of 17 August 2009. The warrants are publicly traded on the London Stock Exchange under the symbol "JPWW."

J.P. Morgan Private Equity LimitedTroy Duncan / Gregory Getschow Telephone: +44 (0) 20 7742 3032 / +1 212 648 1150

Rosemary DeRise Telephone: + 1 212 648 2980

Peregrine CommunicationsAnthony Payne Telephone: +44 (0) 20 3178 6869

* * *

 

VALUATION POLICY AND METHODOLOGY

Valuation reporting policy

 

The Net Asset Value of the Company is calculated by HSBC Management (Guernsey) Limited and published monthly with the relevant Valuation Point being 5.00 p.m. (Guernsey time) on the last Business Day of each month. Each monthly Net Asset Value is published through a Regulatory News Service (RNS) announcement normally within 20 Business Days of such month end. Valuations produced by the Manager as at the relevant month end are conclusive and binding on all Shareholders. In addition to the planned new reporting cycle described above, the Company and the Manager may, in their sole discretion, arrange for additional valuations to be published or extend the 20 Business Day period to cater for exceptional circumstances or significant new developments.

 

 

Private equity valuation methodology

The Board values the investments in the Private Equity Portfolio on the Manager's advice by following the recommendations of either the International Private Equity and Venture Capital Valuation Guidelines (IPEVCG) or standard industry practice. For unquoted fund investments, the value is the most recent valuation placed on a fund by the respective private equity manager, although the Manager may recommend to the Board that an adjustment to such valuation be made if necessary to reflect cash flows between the Company and the fund(s) concerned which occur between the private equity manager's valuation date and the Company's monthly valuation dates. In the event that the Company directly holds publicly traded portfolio companies, the Manager may recommend that an adjustment to such valuation be made if necessary. The Manager will endeavour to include the most recent valuations received by the respective private equity manager at the time in which the monthly Net Asset Value is published.

 

The valuation policies used by many of the private equity managers in undertaking such valuations is generally in line with the recommendations of either the International Private Equity and Venture Capital Valuation Guidelines (IPEVCG) or standard industry practice.

 

All valuations of fund interests include a provision for carried interest, where appropriate, payable to the relevant private equity sponsor.

 

While the Board's normal policy is to adopt the private equity manager's valuations and to reflect in the valuation of the Company Portfolio any adjustment to the valuation of their respective funds made by private equity sponsors, on occasions it may depart from this policy in the following circumstances:

 

·; the Manager may recommend the Board not to adopt an upwards adjustment if in its opinion the adjustment made or proposed by the relevant private equity manager is not prudent;

·; the Manager may recommend that the Board make a downward adjustment to the valuation of a fund interest in the Company Portfolio which has not been made or proposed by the private equity manager if they receive relevant information which has not been notified to them by the private equity manager or if they form a different and more cautious view than that held by the private equity manager; and

·; the Manager may recommend that the Board make an upward adjustment to the valuation of a fund interest in the Company Portfolio which has not been made or proposed by the private equity manager if they receive relevant information that has occurred subsequent to the issuance of the general partner valuation, such as in cases of announcements of the pending public offering or sale of a portfolio company.

 

Secondary Portfolios

The Company may acquire secondary interests at either a premium or a discount to the respective private equity sponsor's valuation by following the International Private Equity and Venture Capital Valuation Guidelines. The Company will maintain values for any secondary interests at the price at which they were purchased until the receipt of the first valuation report from the respective private equity sponsor after the date of acquisition, at which point the acquired interests will be valued according to the Company's standard ongoing valuation methodology.

 

The calculation of the Net Asset Value will only be suspended in circumstances where the underlying data necessary to value the investments of the Company cannot readily, or without undue expenditure, be obtained. Details of any suspension in making such calculations will be announced through an RNS.

 

* * *

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRTTMLTMBJBMMM
Date   Source Headline
15th Nov 20195:52 pmRNSNet Asset Value(s) - September
15th Nov 20195:51 pmRNSNet Asset Value(s) - August 2019
15th Nov 20195:51 pmRNSNet Asset Value(s) - July 2019
5th Nov 20195:42 pmRNS2019 AGM CIRCULAR
22nd Oct 20197:00 amRNSCompletion of Sixth Mandatory Redemption
9th Oct 20193:28 pmRNSSixth Mandatory Redemption
27th Sep 201910:48 amRNSAnnual Financial Report - 30 June 2019
10th Sep 20191:19 pmRNSNet Asset Value(s) - June 2019
12th Jul 20197:00 amRNSNet Asset Value(s) - May 2019
13th Jun 20197:00 amRNSNet Asset Value(s) - April 2019
17th May 20197:00 amRNSNet Asset Value(s) - March 2019
5th Apr 20197:00 amRNSNet Asset Value(s) - February 2019
19th Mar 20193:57 pmRNSHalf-year Report - 31 December 2018
13th Mar 20197:00 amRNSNet Asset Value(s)
7th Feb 201910:55 amRNSNet Asset Value(s) - December 2018
22nd Jan 201910:10 amRNSNet Asset Value(s) - November 2018
8th Jan 20197:00 amRNSCompletion Of Fifth Mandatory Redemption
10th Dec 20183:58 pmRNSMandatory Redemption - US$Equity Shares - Dec 2018
6th Dec 20183:28 pmRNSHolding(s) in Company
30th Nov 20183:21 pmRNSNet Asset Value(s) - October 2018
27th Nov 201811:08 amRNSAGM Results 2018
7th Nov 20187:00 amRNS2018 AGM CIRCULAR
30th Oct 20187:00 amRNSNet Asset Value(s) - August 2018
30th Oct 20187:00 amRNSNet Asset Value(s) - September 2018
30th Oct 20187:00 amRNSNet Asset Value(s) - July 2018
12th Oct 20184:32 pmRNSHolding(s) in Company
4th Oct 20182:42 pmRNSNotification of Dealings in Shares
28th Sep 20181:10 pmRNSAnnual Financial Report - 30 June 2018
17th Sep 20187:00 amRNSNet Asset Value(s) - June 2018
22nd Aug 20185:11 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSNet Asset Value(s) - May 2018
3rd Jul 20187:00 amRNSNet Asset Value(s) - April 2018
9th May 20187:00 amRNSNet Asset Value(s) - March 2018
13th Apr 20189:30 amRNSNet Asset Value(s) - February 2018
11th Apr 20187:00 amRNSNotice to Shareholders - Total Voting Rights
10th Apr 20182:24 pmRNSCompletion of Fourth Mandatory Redemption
22nd Mar 20187:00 amRNSHalf-year Report - 31 December 2017
22nd Mar 20187:00 amRNSMandatory Redemption- US$Equity Shares -April 2018
12th Mar 20187:00 amRNSNet Asset Value(s) - January 2018
2nd Feb 20187:00 amRNSNet Asset Value(s) - December 2017
15th Jan 20187:00 amRNSNet Asset Value(s) - November 2017
29th Dec 20171:15 pmRNSNotice to Shareholders - Key Information Document
14th Dec 20175:50 pmRNSNotice to Shareholders - Total Voting Rights
14th Dec 20177:00 amRNSCompletion Of Third Mandatory Redemption
4th Dec 20172:52 pmRNSAGM Results
4th Dec 20179:44 amRNSNet Asset Value(s) - October 2017 Review
1st Dec 20177:05 amRNSMandatory Redemption - US$Equity Shares - Dec 2017
1st Dec 20177:00 amRNSNet Asset Value(s) - October 2017
24th Nov 20177:00 amRNSSale of Celerion
20th Nov 20172:59 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.